The observed induction of cellular differentiation and subsequent reduction in proliferation following treatment with a hypomethylating agent in IDH mutant glioma is surprisingly consistent with an independent study that is simultaneously reported in this journal [32]. This evidence concerns the gene IDH2 and central nervous system cancer.